The latest National Comprehensive Cancer Network (NCCN) guidelines14 categorized t(8;21) AML with KITmut as an intermediate risk,14 while the 2017 European LeukemiaNet (ELN) Recommendations classified t(8;21) AML as a favorable risk regardless of KIT mutational status.15 Here, KIT is linked to acute myeloid leukemia.